TABLE 1. Patient Demographics.
NYHA = New York Heart Association, VT = Ventricular tachycardia, ICD = Implantable Cardioverter Defibrillator, PVC = Premature ventricular contraction, ATP = Antitachycardia pacing, ACE = Angiotensin Converting Enzyme, ARB = Angiotensin Receptor Blocker, COPD = Chronic Obstructive Pulmonary Disease
| Variable | N = 19 |
|---|---|
| Median Age (year) (range) | 66 (49 – 81) |
| Sex (n) (%) Male Female |
17 (89.5) 2 (10.5) |
| Race (n) Caucasian Black/AA Asian |
17 (89.5) 1 (5.3) 1 (5.3) |
| Median Body Mass Index (kg/m2) (range) | 33.0 (24.3 – 48.6) |
| Median Age-Adjusted Charlson Score (range) | 4 (2 – 13) |
| Type of Cardiomyopathy (n) (%) Ischemic Non-ischemic Idiopathic Myocarditis (chronic) Valvular |
11 (57.9) 8 (42.1) 5 2 1 |
| NYHA Class (n) (%) I II III IV |
1 (5.3) 4 (21.1) 10 (52.6) 4 (21.1) |
| Median Left ventricular ejection fraction (%) (range) |
25 (15 – 58) |
| Median Number of Previous Catheter Ablations (range) |
1 (0–4) |
| Total Number of Prior Catheter Ablation Approaches (n) Endocardial Epicardial |
25 4 |
| Study Eligibility Criteria (n) (%) Incessant VT VT storm (>3 in 24 hours) ICD therapies (>3 shock or ATP in 6 months) PVC-related cardiomyopathy |
2 (10.5) 10 (52.6) 5 (26.3) 2 (10.5) |
| Device (n) (%) Single- or dual-chamber ICD Bi-ventricular ICD None |
8 (42.1) 10 (52.6) 1 (5.3) |
| More than one antiarrhythmic drug at baseline (n) (%) |
11 (57.9) |
| Current Antiarrhythmic drugs (n) (%) High dose amiodarone (≥300mg/day) Low dose amiodarone (<300mg/day) Class III (excluding amiodarone) Class I |
11 (57.9) 1 (5.3) 6 (31.6) 12 (63.2) |
| Other medications (n) (%) Beta-blocker Angiotensin Converting Enzyme (ACE)-Inhibitor Angiotensin Receptor Blocker (ARB) Oral Anticoagulation |
18 (94.7) 10 (52.6) 7 (36.8) 14 (73.7) |
| COPD/emphysema (n) (%) | 4 (21.1) |
| Diabetes Mellitus, Type 2 (n) (%) | 7 (36.8) |
| Hypertension (n) (%) | 10 (52.6) |
| Chronic Kidney Disease, Stage ≥3 (n) (%) | 9 (47.4) |